Pharmaxis banks

By Dylan Bushell-Embling
Tuesday, 16 September, 2008

Pharmaxis [ASX: PXL] ended FY08 in a strong cash position despite large R&D-related losses for the financial year.

At the end of FY08 Pharmaxis had $112 million in the bank, significantly higher than the $76 million cash position the company reported in 2007.

But the company posted a loss of around $20 million for the financial year, largely due to research and development costs.

This R&D spend includes two projects currently progressing their way through clinical trials.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd